0000950170-23-021346.txt : 20230511 0000950170-23-021346.hdr.sgml : 20230511 20230511165023 ACCESSION NUMBER: 0000950170-23-021346 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35776 FILM NUMBER: 23911854 BUSINESS ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 BUSINESS PHONE: 450-686-4555 MAIL ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 8-K 1 acst-20230508.htm 8-K 8-K
false000144419200014441922023-05-082023-05-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 08, 2023

 

 

ACASTI PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Quebec

001-35776

98-1359336

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3009, boul. de la Concorde East

Suite 102

 

Laval, Quebec

 

H7E 2B5

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 450 686-4555

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, no par value per share

 

ACST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 8, 2023, the Company appointed Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer, effective immediately. Dr. Macdonald, 61, is a world-renowned practicing neurosurgeon-scientist and respected authority in subarachnoid hemorrage. Dr. Macdonald acted as Professor, Department of Surgery, Division of Neurosurgery at the University of Toronto from January 2007 until December 2019, and was Head, Division of Neurosurgery, St. Michael's Hospital, University of Toronto from January 2007 until December 2015. He was Professor, Department of Neuorological Surgery, Barrow Neurological Surgery, Barrow Neurological Instituyte, Phoenix, Arizona, from April 2018 until August 2018; Fellow, Department of Neurosurgery, University of Illinois Hospitals in Chicago, Illinois from December 2018 until June 2019; Clinical Professor, Department of Neurological Surgery, University of California San Franciso Fresno, in Fresno, California from July 2019 until September 2021; and from October 2021 to the present has been Neurosurgeon, Community Physicians Group, Community Neurosciences Institute, Community Regional Medical Center and Medical Director of Neurosciences Research, Community Health Partners. Dr Macdonald was also a founder of Edge Therapeutics, Inc. in 2009, where he was a member of the board of directors between 2009 and 2018 and was Chief Scientific Officer between 2011 and 2018. Dr. Macdonald completed his medical degree at the University of British Columbia, Vancouver, British Columbia and his PhD in Experimental Surgery at the University of Alberta in Edmonton, Alberta. He completed his Neurosurgery residency at the University of Toronto.

On May 8, 2023, the Company appointed Carrie D'Andrea as its VP Clinical Operations, effective immediately. Ms. D’Andrea, 51, is a highly experienced professional with 25 years of experience in the pharmaceutical and biotechnology industry who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage. Ms. D'Andrea was the Vice President of Clinical Operations for Edge Therapeutics Inc. from October 2014 until March 2019 and for EryDel SpA from October 2020 until April 2021. Ms. D'Andrea received her master's degree in Pharmaceutical Quality and Regulatory Affairs from Temple University and teaches Clinical Trial Design and Operations at Rutgers University in the Master of Business and Science Program.

On May 8, 2023, the Company appointed Amresh Kumar, PhD, as its VP of Program Management, effective May 15, 2023. Mr. Kumar, 43, is an experienced drug development, CMC, and program management expert supporting investigational and marketed products for rare diseases and neurology. Mr. Kumar is the former product leader of GTX-104 while at Grace Therapeutics Inc. (which was acquired by the Company in August 2021). Mr. Kumar acted as the Sr. Director of Program Management at Foresee Pharmaceuticals Inc. from April 2022 until May 2023 and as Program Leader and Associate Director - R&D at Grace Therapeutics Inc. between March 2015 and January 2022. Mr. Kumar received a PhD in Pharmaceutical Science from Sunrise University, India, focusing on complex injectable drug delivery systems of highly soluable oncology drugs. He has published many research articles and has more than 10 granted patents and many patent applications worldwide to his credit.

None of Dr. Macdonald, Ms D'Andrea or Mr. Kumar is a party to any transaction with the Company that would require disclosure under Item 404(a) of SEC Regulation S-K. In addition, there are no family relationships between any of Dr. Macdonald, Ms. D'Andrea or Mr. Kumar and any current director or executive officer of the Company.

The Company will file an amendment to this Form 8-K disclosing the compensation arrangements for Dr. Macdonald, Ms. D'Andrea or Mr. Kumar for their respective new roles with the Company, once available.

On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US). Mr. Ford will remain as interim Chief Financial Officer of the Company until June 30, 2023, subject to potential extension of that term by the Company. Under the terms of their employment arrangements, Mr. Ford, Mr. Lemieux and Mr. Kottayil will receive severance payments.

Item 8.01 Other Events.

On May 8, 2023, the Company announced the successful submission to the FDA of GTX-104’s full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.

 

The realignment follows a comprehensive strategic review of the Company by Prashant Kohli, its recently appointed chief executive officer, and its Board of Directors.

 

Key strategies being implemented are:

1.
Prioritizing resources to GTX-104. The Company has submitted the full pivotal Phase 3 Safety Study protocol with all supporting documentation. Pending final feedback and approval from the FDA, the first patient, first dose for the pivotal Phase 3 Safety Study is expected in calendar Q4 2023.
2.
Strategic transformation of the Company's operating model to an agile biopharma reflecting its complete focus on GTX-104. In alignment with the operating model, the Company has brought on a highly experienced new management team with deep subject matter knowledge and direct, hands-on clinical trial experience in aSAH.
3.
Significant extension of the Company’s cash runway expected to be sufficient to fund the Company through calendar Q2 2025, facilitating achievement of critical value inflection milestones, including a potential New Drug Application (NDA) filing for GTX-104.
4.
Evaluation of strategic alternatives to maximize value of de-prioritized pipeline assets (GTX-102 and GTX-101) including out-licensing or sale.

 

In connection with the transformation of the operating model, the Company has moved to appoint the following industry experts to its senior management team:

•
Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer. A world-renowned practicing neurosurgeon-scientist and respected authority in SAH, Dr. Macdonald is the former founder of a clinical-stage biotechnology company focused on subarachnoid hemorrhage.
•
Carrie D’Andrea, as VP Clinical Operations. Ms. D’Andrea is a highly experienced professional who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage.
•
Amresh Kumar, PhD, as VP Program Management. Mr. Kumar is an experienced drug development, CMC, and program management expert. Amresh is the former product leader of GTX-104 while at Grace Therapeutics (which was acquired by the Company).

 

As a result of this strategic realignment, the Company is over time discontinuing its operations in Canada, and has proceeded to lay off substantially all its workforce, allowing the Company's new management team to rebuild a leaner organization in the United States. All of the Company's finance team will remain in their current role for a transition period until at least the end June 2023.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Acasti Pharma Inc.

 

 

 

 

Date:

May 11, 2023

By:

/s/ Prashant Kohli

 

 

 

Prashant Kohli, Chief Executive Officer

 

 EX-101.SCH 2 acst-20230508.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 acst-20230508_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 acst-20230508_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
May 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 08, 2023
Entity Registrant Name ACASTI PHARMA INC.
Entity Central Index Key 0001444192
Entity Emerging Growth Company false
Securities Act File Number 001-35776
Entity Incorporation, State or Country Code A8
Entity Tax Identification Number 98-1359336
Entity Address, Address Line One 3009, boul. de la Concorde East
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Postal Zip Code H7E 2B5
City Area Code 450
Local Phone Number 686-4555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol ACST
Security Exchange Name NASDAQ
XML 6 acst-20230508_htm.xml IDEA: XBRL DOCUMENT 0001444192 2023-05-08 2023-05-08 false 0001444192 8-K 2023-05-08 ACASTI PHARMA INC. A8 001-35776 98-1359336 3009, boul. de la Concorde East Suite 102 Laval QC H7E 2B5 450 686-4555 false false false false Common Shares, no par value per share ACST NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acst-20230508.htm acst-20230508.xsd acst-20230508_lab.xml acst-20230508_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acst-20230508.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "acst-20230508.htm" ] }, "labelLink": { "local": [ "acst-20230508_lab.xml" ] }, "presentationLink": { "local": [ "acst-20230508_pre.xml" ] }, "schema": { "local": [ "acst-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230508.htm", "contextRef": "C_f1da8991-d050-4c21-8ff7-767528a1d7fe", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230508.htm", "contextRef": "C_f1da8991-d050-4c21-8ff7-767528a1d7fe", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-021346-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-021346-xbrl.zip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end